Table 3.
Most discriminatory markers per differential diagnosis
| BL | CD10− DLBCL | CD10+ DLBCL | CLL | FL | HCL | LPL | MCL | |
|---|---|---|---|---|---|---|---|---|
| CD10− DLBCL | CD10 (20.7%) | |||||||
| CD45 (16.6%) | ||||||||
| CD10+ DLBCL | CD45 (24.8%) | CD10 (29.4%) | ||||||
| CD19 (18.5%) | CD19 (11.7%) | |||||||
| CLL | CD10 (15.2%) | CD5 (10.9%) | CD10 (12%) | |||||
| CD200 (14.5%) | BT ratio (10.1%) | CD19 (11.3%) | ||||||
| FL | CD45 (23.3%) | CD10 (20.9%) | BT ratio (19.9%) | CD5 (10.8%) | ||||
| CD38 (14.9%) | CD43 (9.7%) | CD19 (18.2%) | CD43 (9.7%) | |||||
| HCL | CD38 (11.1%) | CD305 (20.7%) | CD19 (14.0%) | CD11c (8.9%) | CD305 (16.4%) | |||
| CD305 (11.0%) | CD103 (13.9%) | CD22 (8.7%) | CD5 (8.8%) | CD11c (14.1%) | ||||
| LPL | CD45 (18.4%) | CD45 (13.0%) | CD10 (21.9%) | CD45 (12.3%) | CD10 (17.6%) | CD45 (16.7%) | ||
| CD10 (17.9%) | CD22 (12.7%) | CD31 (11.2%) | CD5 (11.9%) | CD31 (16.7%) | CD11c (10.8%) | |||
| MCL | CD10 (25.9%) | CD200 (12.5%) | CD10 (24.4%) | CD200 (25.3%) | CD5 (15.4%) | CD11c (14.0%) | CD5 (14.3%) | |
| CD45 (17.8%) | CD95 (10.9%) | CD95 (11.8%) | IgM (8.0%) | CD10 (13.6%) | CD5 (11.8%) | CD45 (10.7%) | ||
| MZL | CD10 (19.2%) | CD20 (9.0%) | CD10 (25.2%) | CD5 (15%) | CD10 (20.8%) | CD45 (18.1%) | CD22 (11.3%) | CD5 (19.4%) |
| CD45 (15.9%) | CD81 (8.9%) | CD19 (15.6%) | CD19 (11.2%) | BT ratio (10.6%) | CD103 (15.2%) | CD31 (8.9%) | CD19 (12.2%) |
Each cell of the table contains the marker with highest weight contributing to the first canonical axis on top and the marker with the second-highest contribution at the bottom. The significance of the markers is provided in brackets.